Remission induction with daunomycin, vincristine, and prednisone in adult acute lymphocytic leukemia.
Prednisone plus vincristine plus daunomycin induced complete remission in nine adults with acute lymphocytic leukemia. The median duration of complete remission will be between 14 and 18 months, with three patients remaining in hematological remission at 10+, 11+, and 18+ months. The median survival will be between 19 and 23 months, with all patients surviving at least one year. This remission induction regimen produced rapid complete remission in adult acute lymphocytic leukemia (ALL) with minimal toxicity, and could be administered predominantly on an outpatient basis.
D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000517:prevention & control; D003630:Daunorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D013120:Spinal Cord Neoplasms / Q000517:prevention & control; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine; D011241:Prednisone; D003630:Daunorubicin